The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Neuromuscular Disorders Market Projected To Reach By 2030?
The market size for neuromuscular disorders has experienced substantial growth in recent years. This market is projected to expand from $8.31 billion in 2025 to $8.98 billion in 2026, at a compound annual growth rate (CAGR) of 8.0%. The historical growth of this market is attributable to several factors, including the increasing prevalence of genetic neuromuscular conditions, enhanced awareness regarding early diagnosis and treatment options, a rising demand for effective therapies for rare disorders, increased research initiatives focused on conditions like muscular dystrophy and ALS, and the growing adoption of advanced diagnostic technologies.
The neuromuscular disorders market is projected to experience substantial expansion over the next few years, with its size expected to reach $12.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is primarily driven by an increase in patient advocacy and support group activities, a rising demand for biologics and gene therapies, enhanced recognition of neuromuscular disorders in pediatric populations, growing government initiatives for managing rare diseases, and a greater emphasis on home-based care and rehabilitation services. Furthermore, significant trends expected in this period include advancements in gene-editing technologies for targeted therapies, innovative developments in RNA-based treatment platforms, the integration of AI for more efficient neuromuscular diagnosis, progress in stem-cell-based regenerative treatments, and novel innovations in wearable devices for continuous patient monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30678&type=smp
Which Strong Drivers Are Impacting The Neuromuscular Disorders Market Growth?
Increased demand for personalized medicine is projected to drive the expansion of the neuromuscular disorders market. This medical approach customizes treatments for individual patients, considering their genetic, environmental, and lifestyle elements to enhance results and care. Its demand is growing due to progress in genomic technologies, which facilitate accurate identification of genetic variations and the development of customized therapies. Personalized medicine improves the management of neuromuscular disorders by customizing therapies according to unique genetic, molecular, and physiological profiles. This leads to better patient outcomes through targeted therapies, improved effectiveness, and reduced side effects. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit, revealed that the U.S. Food and Drug Administration (FDA) authorized 26 new personalized medicines in 2023, marking a notable rise from the 12 approvals in 2022. Consequently, the increasing need for personalized medicine is fueling the growth of the neuromuscular disorders market.
Which Segment Types Are Examined In The Neuromuscular Disorders Market Segment Study?
The neuromuscular disorders market covered in this report is segmented –
1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies
2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices
3) By Route of Administration: Oral, Injectable, Other Route of Administrations
4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care
Subsegments:
1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)
2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS
3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations
4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG
5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy
Which Trends Are Contributing To Changes In The Neuromuscular Disorders Market?
Major companies in the neuromuscular disorders market are prioritizing the development of advanced treatments, such as gene replacement therapies, to address the underlying genetic causes of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy encompasses engineered biological products that deliver functional copies of defective genes to restore or improve muscle function in patients with inherited neuromuscular conditions, offering a potential one-time treatment that reduces the need for long-term chronic therapy. For instance, in November 2025, Novartis, a Switzerland-based pharmaceuticals company, received US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve), recognized as the first and only gene replacement therapy for the treatment of children two years of age and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in the survival motor neurone 1 (SMN1) gene. It is specifically formulated to treat the genetic underlying cause of SMA with a single, fixed dosage that does not require body weight or age adjustments. Itvisma can enhance motor function by substituting the SMN1 gene, which may lessen the requirement for long-term medication used in conjunction with other current treatments for this population.
Which Players Are Part Of The Competitive Landscape Of The Neuromuscular Disorders Market?
Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.
Get The Full Neuromuscular Disorders Market Report:
https://www.thebusinessresearchcompany.com/report/neuromuscular-disorders-market-report
Which Geographic Region Dominates The Neuromuscular Disorders Market?
North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neuromuscular Disorders Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=30678&type=smp
Browse Through More Reports Similar to the Global Neuromuscular Disorders Market 2026, By The Business Research Company
Muscle Spasticity Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report
Muscle Wasting Disorders Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report
neurological disorder drugs global market report
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model